Pyrotinib: First Global Approval-Reference-Cited by-同舟云学术

Pyrotinib: First Global Approval

Published:2018-10-19 Issue:16 Volume:78 Page:1751-1755
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Blair Hannah A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-018-0997-0/fulltext.html

Reference11 articles.

1. Escriva-de-Romani S, Arumi M, Bellet M, et al. HER2-positive breast cancer: current and new therapeutic strategies. Breast. 2018;39:80–8.

2. Ponde N, Brandao M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10–20.

3. Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51–61.

4. De Leon J. China approves Hengrui breast cancer drug on phase II data; 2018. https://www.biocentury.com/bc-extra/company-news/2018-08-22/china-approves-hengrui-breast-cancer-drug-phase-ii-data . Accessed 25 Sep 2018.

5. Lovells H. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs; 2018. https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1 . Accessed 3 Sept 2018.

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

3. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

4. An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents;European Journal of Medicinal Chemistry;2024-09

5. Case report: Pyrotinib and tegafur combined with radiotherapy achieved notable response in HER2-amplified rectal cancer with multiple metastases after multiline treatments;Frontiers in Pharmacology;2024-08-13